Ireland
--:--IST
Latest
Clinical Trials in France / NCT07818551
Starting soon Not applicable

Assessment of Pain Perception and the Impact of Central Sensitization on Biopsychosocial Manifestations During Physical Activity in Patients With Chronic Low Back Pain

NCT07818551 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2026-09-20
Last updated
2026-09-18

Condition(s) studied

Chronic Low Back Pain

Investigational drug(s) / intervention(s)

Exercise rehabilitation on an ergocycle

Exercise rehabilitation on an ergocycle: Following enrolment, patients will undergo a calibration test on an ergocycle on Day 1 to determine the power required to maintain a constant moderate effort corresponding to an intensity of 4-5/10 on the modified Borg scale. Then, to assess the pain-inducing potential of exercise on the ergocycle, they will undertake two tests (on Day 3 and Day 5) to evaluate changes in pain during constant moderate exertion. During their rehabilitation programme for low back pain, patients will undergo exercise retraining on the ergocycle. From Day 8 to Day 40 (three times a week, on Mondays, Wednesdays and Fridays), the patients' perception of exertion will be assessed at the end of each exercise bike session to ensure that they are maintaining a constant moderate level of exertion. Patients will be assessed on Day 40 to collect data on cognitive and behavioural markers related to central sensitisation and pain intensity, as at baseline.

Study summary

The goal of this prospective observational study is to evaluate changes in cognitive and behavioural markers associated with central sensitisation between the start and end of an exercise retraining programme on an exercise bike, in adult patients suffering from chronic lower back pain associated with an untreated degenerative spine, worth or without referred pain.

The main changes it will evaluate are:

\- Changes in cognitive and behavioural markers associated with central sensitisation between Day 0 and Day 40 during exercise retraining on an exercise bike as part of a rehabilitation programme for chronic low back pain

Participants will undergo the followings:

* A calibration test used to define moderate exertion on an ergocycle, corresponding to a perceived exertion of 4-5/10 on the modified Borg scale
* Exercise-induced pain intensity assessment tests to detect changes in the intensity of pain during physical activity and the activity's potential to cause pain, realised on ergocyle
* Exercise rehabilitation on an ergocycle
* Final tests to assess cognitive and behavioural markers related to central sensitisation and pain intensity, as at baseline.

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria: * Adult patients, ages 18 through 75 inclusive, admitted to the Musculoskeletal Rehabilitation Unit at the Concarneau Regional Hospital * Chronic low back pain due to degenerative spine disease that has not been treated surgically, with or without referred pain * Low back pain intensity of 4/10 or less on the EVA scale * Pain lasting more than 12 months (= critical period for cerebral impairment) * Oswestry score between 21% and 40% * CSI score of 33/100 or higher for women and 25/100 or higher for men * Patients enrolled in or covered by a social security program * Patients who have signed a consent form Exclusion Criteria: * Patients with acute low back pain of traumatic or neoplastic origin * Patients with a contraindication to moderate-intensity physical activity (Borg 4-5/10 on the modified Borg scale) * Inability to participate in sessions due to pain unrelated to low back pain or a disability * Pregnant or breastfeeding patients * Patients under legal guardianship or conservatorship

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
SMR pôle Réadaptation de Cornouaille Concarneau France

More University Hospital, Brest trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07818551 on ClinicalTrials.gov ↗ ← All trials in France